Videos

Hedy Lee Kindler, MD, shares new mesothelioma guidelines that have been released by the American Society of Clinical Oncology.

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

Deborah Wong, MD, PhD, discusses therapeutic options for patients with nasopharyngeal carcinoma.

Rodabe Amaria, MD, discusses the current role of OBX-115 for the treatment of patients with checkpoint inhibitor-resistant metastatic melanoma.

Wojciech Jurczak, MD, PhD, ​​discusses nemtabrutinib and its development for the treatment of follicular lymphoma.

An expert discusses how quality-of-life assessments guide treatment strategies for patients with myeloproliferative neoplasms (MPNs).

An expert discusses insights from MAJIC-PV, MANIFEST-2, and other relevant trials and how these studies help advance the management of myeloproliferative neoplasms (MPNs).

Seth Wander, MD, PhD, discusses approved and upcoming targeted therapies for patients with ESR1-mutated breast cancer.

Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at a level of 1 or higher.

An expert discusses other ongoing investigations exploring radium-223-based combinations for the treatment of metastatic castration-resistant prostate cancer, highlighting key studies and their potential impact on clinical practice.

An expert discusses how, for advanced unresectable hepatocellular carcinoma (uHCC), clinicians monitor treatment efficacy through imaging, α-fetoprotein levels, and tolerability. Treatment decisions are guided by response assessment, adverse events, and liver function. First-line (1L) options include tyrosine kinase inhibitors and immunotherapy combinations, with promising trials exploring novel immune combinations and targeted approaches that may reshape the treatment landscape.

An expert discusses other ongoing investigations exploring radium-223-based combinations for the treatment of metastatic castration-resistant prostate cancer, highlighting key studies and their potential impact on clinical practice.

Panelists discuss how emerging evidence suggests that combining transarterial chemoembolization (TACE) with systemic therapy could redefine the standard of care for hepatocellular carcinoma (HCC). Trial outcomes may drive shifts toward more personalized locoregional approaches. However, challenges in implementation include optimizing patient selection, managing toxicity, and ensuring multidisciplinary coordination.

Panelists discuss how the role of systemic therapy in intermediate-stage hepatocellular carcinoma (HCC) is evolving with combinations like immunotherapy and targeted agents enhancing locoregional treatment. LEAP-012 and EMERALD-1 evaluate lenvatinib + pembrolizumab and durvalumab-based regimens with transarterial chemoembolization (TACE), respectively. Their findings may redefine treatment paradigms, improving outcomes and expanding therapeutic options.

An expert discusses what has been learned about the use of bone-protecting agents and bone density scans for patients receiving an androgen receptor pathway inhibitor (ARPI) in combination with radium-223, based on data from the Phase 3 PEACE-3 study (Enza + Ra-223) and the Phase 3 ERA-223 study (AAP + Ra-223).

An expert discusses how in the first-line (1L) treatment of advanced unresectable hepatocellular carcinoma (uHCC) with tyrosine kinase inhibitors (TKIs) such as lenvatinib or sorafenib, proactive adverse event (AE) management is crucial. This includes baseline assessment; regular monitoring of adverse effects such as hypertension, hand-foot syndrome, and fatigue; and implementing preventive strategies. Treatment should be individualized with dose modifications as needed to balance therapeutic efficacy with quality of life, particularly given the advanced disease state.

Rodabe N. Amaria, MD, explains a trial of OBX-115, a novel engineered tumor infiltrating lymphocyte therapy, in checkpoint inhibitor-resistant metastatic melanoma.

An expert discusses how the availability of subcutaneous (SC) immune checkpoint inhibitors (ICI) for bladder cancer impacts treatment selection by offering improved convenience and accessibility, particularly in advanced/metastatic and perioperative settings. SC formulations may reduce costs, time, and patient burden while enhancing treatment compliance and follow-up.

An expert discusses how medical professionals counsel eligible patients about adjuvant immune checkpoint inhibitor (ICI) therapy by discussing its potential to reduce cancer recurrence, emphasizing the benefits in high-risk cases. They carefully assess patient eligibility, explaining potential immune-related adverse events and balancing these risks with the treatment’s potential lifesaving benefits.

Panelists discuss the management of adverse events (AEs) associated with ROS1 inhibition, emphasizing strategies for prevention, monitoring, and treatment of adverse effects.

An expert discusses how medical professionals monitor and manage adverse events (AEs) with adjuvant nivolumab through regular assessments, including laboratory tests and clinical evaluations. While approaches may overlap with metastatic settings, adjuvant treatment often emphasizes early detection of immune-related AEs, as patients are generally healthier.

An expert discusses how medical professionals are increasingly utilizing circulating tumor DNA (ctDNA) and tissue PD-L1 to guide recommendations for adjuvant immune checkpoint inhibitor (ICI) therapy. ctDNA helps monitor minimal residual disease and early treatment response while tissue PD-L1 status aids in predicting ICI efficacy, optimizing patient treatment plans.

An expert discusses how enthusiasm for adjuvant anti–PD-1 therapy varies based on key factors. Receipt of neoadjuvant chemotherapy (NAC), nodal involvement, positive margins, variant histology, and PD-L1 expression influence recommendations. Observation may be preferred in frail, elderly, or autoimmune-prone patients. muscle-invasive urothelial carcinoma (MIBC) status is critical in decision-making.

Panelists discuss treatment decision-making for metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, focusing on targeted therapies and personalized treatment strategies.

M. Michele Blackwood, MD, FACS, highlights an innovative trial delivering 1 week of pre-surgery and 2 weeks of post-surgery radiation for patients with breast cancer.

An expert discusses how medical professionals have integrated tagraxofusp into blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment, leveraging its CD123-targeted efficacy per 0114 trial data. Real-world findings (Angelucci et al, ASH 2023) align with clinical outcomes, reinforcing tagraxofusp’s role in BPDCN management by supporting its safety and effectiveness in broader settings.

An expert discusses how, historically, blastic plasmacytoid dendritic cell neoplasm (BPDCN) was treated with regimens for acute leukemia or lymphoma. Current NCCN guidelines recommend intensive multiagent chemotherapy followed by allogeneic stem cell transplantation, when possible, with targeted therapies like tagraxofusp now available for specific cases.

An expert discusses how medical professionals counsel patients on adverse event (AE) risks with tyrosine kinase inhibitors (TKIs) such as lenvatinib/everolimus by highlighting key safety distinctions, including hypertension (HTN), fatigue, and diarrhea. For third-line tivozanib, tolerability and common toxicities (eg, Palmar-Plantar Erythrodysesthesia (PPE), HTN) are considered. AE incidence, discontinuation rates, and drug interactions guide treatment choices. Managing toxicities involves prevention, monitoring, and mitigation strategies, with dose modifications tailored based on severity and combination regimens. Community oncologists are advised on proactive AE management to optimize outcomes.

Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Cedric Pobel, MD, covers the PEACE-1 trial of radiotherapy, standard of care, and abiraterone in low-volume metastatic castration-sensitive prostate cancer.